Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial).

[1]  I. Seong,et al.  Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease , 2006, Circulation.

[2]  Seung‐Jung Park,et al.  Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. , 2006, The American journal of cardiology.

[3]  A. Kastrati,et al.  Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents , 2006, Circulation.

[4]  P. Serruys,et al.  Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. , 2006, JAMA.

[5]  Seung‐Jung Park,et al.  Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. , 2006, The American journal of cardiology.

[6]  K. Seung,et al.  Comparison of sirolimus‐eluting stent, paclitaxel‐eluting stent, and bare metal stent in the treatment of long coronary lesions , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  R. Morishita.  A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. , 2005, Atherosclerosis. Supplements.

[8]  J. Popma,et al.  Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice , 2005, Circulation.

[9]  E. Orav,et al.  Robustness of Late Lumen Loss in Discriminating Drug-Eluting Stents Across Variable Observational and Randomized Trials , 2005, Circulation.

[10]  C. Grines,et al.  Coronary Stent Restenosis in Patients Treated With Cilostazol , 2005, Circulation.

[11]  I. Iakovou,et al.  Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. , 2005, Journal of the American College of Cardiology.

[12]  G. Stone,et al.  Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. , 2005, Journal of the American College of Cardiology.

[13]  Seung‐Jung Park,et al.  Comparison of cilostazol and clopidogrel after successful coronary stenting. , 2005, The American journal of cardiology.

[14]  M. Mochizuki,et al.  Comparison of Cilostazol and Ticlopidine for One-Month Effectiveness and Safety after Elective Coronary Stenting , 2004, Cardiovascular Drugs and Therapy.

[15]  P. Serruys,et al.  Very long sirolimus-eluting stent implantation for de novo coronary lesions. , 2004, The American journal of cardiology.

[16]  Seung‐Jung Park,et al.  Effects of cilostazol on angiographic restenosis after coronary stent placement. , 2000, The American journal of cardiology.

[17]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[18]  Seung‐Jung Park,et al.  Comparison of cilostazol versus ticlopidine therapy after stent implantation. , 1999, The American journal of cardiology.

[19]  AtsunoriFukuhara,et al.  Impact of Cilostazol on Restenosis After Percutaneous Coronary Balloon Angioplasty , 1999 .

[20]  K. Kichikawa,et al.  Pharmacologic Treatment of Intimal Hyperplasia After Metallic Stent Placement in the Peripheral Arteries: An Experimental Study , 1995, Investigative radiology.

[21]  J. Polson,et al.  Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. , 1994, Biochemical pharmacology.

[22]  B. Gersh.  Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents , 2006 .

[23]  U. Deligonul.  Coronary Morphologic andClinical Determinants ofProcedural OutcomeWith Angioplasty forMultivessel Coronary Disease Implications forPatient Selection , 1990 .